Future studies will validate the scope of these mechanisms in additional glioma cell lines by analysis of direct POSTN promoter interactions, effects of kinase inhibition and establishing in vivo phenotypes in xenograft models. This evidence concerns the gene POSTN and central nervous system cancer.